Inhibiting platelet desialylation and/or blocking hepatocyte ASGPRs may alleviate thrombocytopenia in ITP patients, especially those with positive cytotoxicity of CD8+ T cells and those who respond poorly to conventional first- and second-line therapies. The gene discussed is CD8A; the disease is autoimmune thrombocytopenic purpura.